Justin R Kingery1, Yona Alfred2, Luke R Smart3, Emily Nash4, Jim Todd5, Mostafa R Naguib6, Jennifer A Downs3, Samuel Kalluvya2, Johannes B Kataraihya2, Robert N Peck1. 1. Department of Internal Medicine, Catholic University of Health and Allied Sciences, Mwanza, Tanzania Department of Internal Medicine, Bugando Medical Centre, Mwanza, Tanzania Division of Hospital Medicine, Department of Internal Medicine, Weill Cornell Medical College, New York City, New York, USA Department of Internal Medicine, Center for Global Health, Weill Cornell Medical College, New York City, New York, USA. 2. Department of Internal Medicine, Catholic University of Health and Allied Sciences, Mwanza, Tanzania Department of Internal Medicine, Bugando Medical Centre, Mwanza, Tanzania. 3. Department of Internal Medicine, Catholic University of Health and Allied Sciences, Mwanza, Tanzania Department of Internal Medicine, Bugando Medical Centre, Mwanza, Tanzania Department of Internal Medicine, Center for Global Health, Weill Cornell Medical College, New York City, New York, USA. 4. Department of Internal Medicine, Center for Global Health, Weill Cornell Medical College, New York City, New York, USA. 5. Population Health Department, London School of Hygiene & Tropical Medicine, London, UK. 6. Department of Medicine, Weill Cornell Medical College-Qatar, Doha, Qatar.
Abstract
OBJECTIVE: To compare short-term and long-term cardiovascular disease (CVD) risk scores and prevalence of metabolic syndrome in HIV-infected adults receiving and not receiving antiretroviral therapy (ART) to HIV-negative controls. METHODS: A cross-sectional study including 151 HIV-infected, ART-naive, 150 HIV-infected on ART and 153 HIV-negative adults. Traditional cardiovascular risk factors were determined by standard investigations. The primary outcome was American College of Cardiology/American Heart Association Atherosclerotic CVD (ASCVD) Risk Estimator lifetime CVD risk score. Secondary outcomes were ASCVD 10-year risk, Framingham risk scores, statin indication and metabolic syndrome. RESULTS: Compared with HIV-negative controls, more HIV-infected adults on ART were classified as high lifetime CVD risk (34.7% vs 17.0%, p<0.001) although 10-year risk scores were similar, a trend which was similar across multiple CVD risk models. In addition, HIV-infected adults on ART had a higher prevalence of metabolic syndrome versus HIV-negative controls (21.3% vs 7.8%, p=0.008), with two common clusters of risk factors. More than one-quarter (28.7%) of HIV-infected Tanzanian adults on ART meet criteria for statin initiation. CONCLUSIONS: HIV-infected ART-treated individuals have high lifetime cardiovascular risk, and this risk seems to develop rapidly in the first 3-4 years of ART as does the development of clusters of metabolic syndrome criteria. These data identify a new subgroup of low short-term/high-lifetime risk HIV-infected individuals on ART who do not currently meet criteria for CVD risk factor modification but require further study. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVE: To compare short-term and long-term cardiovascular disease (CVD) risk scores and prevalence of metabolic syndrome in HIV-infected adults receiving and not receiving antiretroviral therapy (ART) to HIV-negative controls. METHODS: A cross-sectional study including 151 HIV-infected, ART-naive, 150 HIV-infected on ART and 153 HIV-negative adults. Traditional cardiovascular risk factors were determined by standard investigations. The primary outcome was American College of Cardiology/American Heart Association Atherosclerotic CVD (ASCVD) Risk Estimator lifetime CVD risk score. Secondary outcomes were ASCVD 10-year risk, Framingham risk scores, statin indication and metabolic syndrome. RESULTS: Compared with HIV-negative controls, more HIV-infected adults on ART were classified as high lifetime CVD risk (34.7% vs 17.0%, p<0.001) although 10-year risk scores were similar, a trend which was similar across multiple CVD risk models. In addition, HIV-infected adults on ART had a higher prevalence of metabolic syndrome versus HIV-negative controls (21.3% vs 7.8%, p=0.008), with two common clusters of risk factors. More than one-quarter (28.7%) of HIV-infected Tanzanian adults on ART meet criteria for statin initiation. CONCLUSIONS:HIV-infected ART-treated individuals have high lifetime cardiovascular risk, and this risk seems to develop rapidly in the first 3-4 years of ART as does the development of clusters of metabolic syndrome criteria. These data identify a new subgroup of low short-term/high-lifetime risk HIV-infected individuals on ART who do not currently meet criteria for CVD risk factor modification but require further study. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: T Bärnighausen; T Welz; V Hosegood; J Bätzing-Feigenbaum; F Tanser; K Herbst; C Hill; M-L Newell Journal: J Hum Hypertens Date: 2007-11-29 Impact factor: 3.012
Authors: David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson; Harmon S Jordan; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli Journal: Circulation Date: 2013-11-12 Impact factor: 29.690
Authors: André J Tremblay; Hugo Morrissette; Jean-Marc Gagné; Jean Bergeron; Claude Gagné; Patrick Couture Journal: Clin Biochem Date: 2004-09 Impact factor: 3.281
Authors: Farrah J Mateen; Steve Kanters; Robert Kalyesubula; Barbara Mukasa; Esther Kawuma; Andre P Kengne; Edward J Mills Journal: J Hypertens Date: 2013-07 Impact factor: 4.844
Authors: Louise M Goff; Gary S Frost; Gavin Hamilton; E Louise Thomas; Waljit S Dhillo; Anne Dornhorst; Jimmy D Bell Journal: Br J Nutr Date: 2003-03 Impact factor: 3.718
Authors: Robert N Peck; Rehema Shedafa; Samuel Kalluvya; Jennifer A Downs; Jim Todd; Manikkam Suthanthiran; Daniel W Fitzgerald; Johannes B Kataraihya Journal: BMC Med Date: 2014-07-29 Impact factor: 8.775
Authors: Javed Butler; Stephen J Greene; Svati H Shah; Sanjiv J Shah; Kevin J Anstrom; Raymond J Kim; Andreas P Kalogeropoulos; Eric J Velazquez; Adrian F Hernandez; Patrice Desvigne-Nickens; Rebecca Scherzer; Priscilla Y Hsue; Eugene Braunwald Journal: J Card Fail Date: 2019-11-02 Impact factor: 5.712
Authors: Javed Butler; Andreas P Kalogeropoulos; Kevin J Anstrom; Priscilla Y Hsue; Raymond J Kim; Rebecca Scherzer; Sanjiv J Shah; Svati H Shah; Eric J Velazquez; Adrian F Hernandez; Patrice Desvigne-Nickens; Eugene Braunwald Journal: J Card Fail Date: 2018-03-02 Impact factor: 5.712
Authors: Katherine Davis; Pablo Perez-Guzman; Annika Hoyer; Ralph Brinks; Edward Gregg; Keri N Althoff; Amy C Justice; Peter Reiss; Simon Gregson; Mikaela Smit Journal: BMC Med Date: 2021-05-13 Impact factor: 8.775